Objective To compare the clinical features of children with different clinical forms of congenital hepatic fibrosis (CHF), and provides a description of the characteristics of childhood CHF. Methods Sixty children with CHF between January 2002 and June 2015 were enrolled, including 26 children with portal hypertensive CHF (PH CHF), 3 children with cholangitic CHF, 30 children with combined portal hypertensive and cholangitic CHF (mixed CHF), and 1 child with latent forms of CHF. The medical data of 26 children with PH CHF and 30 children with mixed CHF, including gender, age, clinical manifestations, physical signs, laboratory tests and imaging characteristics, were retrospectively studied. Results Fever, jaundice and hepatomegaly were more frequently noted in children with mixed CHF than in those with PH CHF (P<0.05). Splenomegaly and liver cirrhosis occurred more often in children with CHF, but there was no significant difference in the incidences of splenomegaly and liver cirrhosis between the children with PH CHF and mixed CHF. The plasma prothrombin activity, white blood cell counts, platelet counts, mean platelet volume, serum levels of alanine transaminase, aspartate transaminase, alkaline phosphatase, γ-glutamyl transferase, leucine aminopeptidase, and total bile acids in children with mixed CHF were higher than in those with PH CHF (P<0.05). The decreased international normalized ratio and lower serum albumin levels were more frequently observed in children with mixed CHF than in those with PH CHF (P<0.05). Conclusions PH and mixed CHF are common forms in childhood CHF. The children with the two forms of PH usually manifest portal hypertension such as cirrhosis and hepatosplenomegaly. The liver damage may be common in children with mixed CHF.
Key words
Congenital hepatic fibrosis /
Portal hypertension /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Locatelli L, Cadamuro M, Spirli C, et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis[J]. Hepatology, 2016, 63(3): 965-982.
[2] Desmet VJ. What is congenital hepatic fibrosis?[J]. Histopathology, 1992, 20(6): 465-477.
[3] 吴欣, 李忠斌, 刘红虹, 等. 35例先天性肝纤维化患者的临床及病理特点[J]. 胃肠病学和肝病学杂志, 2013, 22(6): 529-532.
[4] Arnon R, Rosenberg HK, Suchy FJ. Caroli disease, caroli syndrome, and congenital hepatic fibrosis[M]. Farmington: Humana Press, 2010: 331-358.
[5] Desmet VJ. Ludwig symposium on biliary disorders—part I. Pathogenesis of ductal plate abnormalities[J]. Mayo Clin Proc, 1998, 73(1): 80-89.
[6] Veigel MC, Prescott-Focht J, Rodriguez MG, et al. Fibropolycystic liver disease in children[J]. Pediatr Radiol, 2009, 39(4): 317-327.
[7] 吴欣, 周超, 罗生强. 先天性肝纤维化不同分型的临床特征— 75例分析[J]. 肝脏, 2014, 19(7): 479-482, 490.
[8] P a r k S M . T h e c r u c i a l r o l e o f c h o l a n g i o c y t e s i n cholangiopathies[J]. Gut Liver, 2012, 6(3): 295-304.
[9] Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease[J]. Dev Dyn, 2008, 237(8): 2007-2012.
[10] 胆汁淤积性肝病诊断治疗专家共识 2015年更新专家委员会. 胆汁淤积性肝病诊断治疗专家共识: 2015年更新[J]. 临床肝胆病杂志, 2015, 13(10): 1563-1574.
[11] Karpen SJ. Update on the etiologies and management of neonatal cholestasis[J]. Clin Perinatol, 2002, 29(1): 159-180.
[12] Woolbright BL, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury[J]. World J Gastroenterol, 2012, 18(36): 4985-4993.
[13] Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis[J]. Am J Pathol, 2011, 178(1): 175-186.
[14] Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts[J]. J Gastroenterol Hepatol, 2011, 26 Suppl 1: 173-179.
[15] Laschke MW, Dold S, Menger MD, et al. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis[J]. Br J Pharmacol, 2008, 153(1): 148-156.
[16] Sullivan BP, Wang R, Tawfik O, et al. Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies[J]. Toxicol Sci, 2010, 115(1): 286-294.
[17] Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues[J]. Platelets, 2002, 13(5-6): 301-306.
[18] Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum[J]. Semin Immunopathol, 2012, 34(1): 5-30.
[19] Poupon R. Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation[J]. Hepatology, 2015, 61(6): 2080-2090.
[20] Kuntz E, Kuntz HD. Cholestasis[M]//Kuntz E, Kuntz HD. Hepatology principles and practice. 2nd. Wetzlar: Springer Berlin Heidelberg, 2006: 227-242.
[21] Lazaridis K N, Strazzabosco M, Larusso N F. The cholangiopathies: disorders of biliary epithelia[J]. Gastroenterology, 2004, 127(5): 1565-1577.
PDF(1228 KB)
